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Abstract: Adults with Down syndrome (DS) are predisposed to obstructive sleep apnoea (OSA),
but the effectiveness and acceptability of continuous positive airway pressure treatment (CPAP) in
this group has rarely been formally assessed. This study was designed as a pilot randomised, parallel
controlled trial for one month, continuing as an uncontrolled cohort study whereby the control
group also received the intervention. Symptomatic, community-dwelling DS individuals exhibiting
≥10 apnoeas/hypopneas per hour in bed on a Type 3 home sleep study were invited to participate
in this study, with follow-up at 1, 3, 6, and 12 months from baseline. Measurements of sleepiness,
behaviour, cognitive function and general health were undertaken; the primary outcome was a
change in the pictorial Epworth Sleepiness Scale (pESS) score. Twenty-eight participants (19 male)
were enrolled: age 28 ± 9 year; body mass index 31.5 ± 7.9 kg/m2; 39.6 ± 32.2 apnoeas/hypopneas per
hour in bed; pESS 11 ± 6/24. The pilot randomised controlled trial at one month demonstrated no
change between the groups. At 12 months, participant (p = 0.001) pESS and Disruptive (p < 0.0001),
Anxiety/Antisocial (p = 0.024), and Depressive (p = 0.008) behaviour scores were reduced compared to
baseline. Improvement was noted in verbal (p = 0.001) and nonverbal intelligence scores (p = 0.011).
General health scores also improved (p = 0.02). At the end of the trial, 19 participants continued
on treatment. Use of CPAP in adults with DS and OSA led to a number of significant, sustained
improvements in sleepiness and behavioural/emotional outcomes at 12 months.
Keywords: obstructive sleep apnoea syndrome; developmental behaviour checklist-adults; down
syndrome; continuous positive airway pressure; cognition; cognitive testing in down syndrome;
adults; pilot randomised controlled trial
1. Introduction
Down syndrome, present in one in 1000 live births worldwide [1], is the commonest form of
intellectual disability. Current estimates suggest that >47,000 people in the UK and >250,000 people in
the USA have Down syndrome [2,3].
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Sleep-disordered breathing, characterised by repetitive pauses in breathing during sleep, affects
24% of the general adult population [4]. Obstructive sleep apnoea syndrome (OSAS) is diagnosed when
nocturnal apnoea results in significant diurnal symptoms, including excessive daytime somnolence,
impaired cognitive function, reduced quality of life, and behavioural and emotional disturbances [5].
The adult prevalence of OSAS in the general population is 5–7% [5], rising to 35–37% in adults with
Down syndrome [6]. OSAS is considered an independent risk factor for cardiovascular morbidity and
mortality, including hypertension, myocardial infarction and stroke [5,7].
The Down syndrome phenotype includes a flattened face, short neck, generalised hypotonia, loose
ligaments, and a tendency toward weight gain—all risk factors for OSAS. Down syndrome causes
cognitive impairment per se, so additional consequences of OSAS may conceivably be more profound
due to lack of existing cognitive reserve [8].
Continuous positive airway pressure (CPAP) therapy is the gold-standard treatment for
moderate-severe OSAS in adults, and is effective in ameliorating OSAS consequences, including
excessive daytime, cognitive dysfunction and metabolic and cardiovascular outcomes in the general
population although the data are not always consistent [9–12]. CPAP use has been shown to reduce
the risk of all-cause mortality to a similar level as the general, non-OSAS, population [13]. However,
despite the potential benefits, diagnosis and treatment of OSAS in adults with Down syndrome is
not commonplace, and, to date, no objective studies of CPAP effectiveness in the Down syndrome
population have been published. This study aimed to assess the effectiveness and acceptability of CPAP
in adults with Down syndrome and OSAS living in the UK, with reference to subjective sleepiness,
behavioural and emotional function, cognitive function, and general health.
2. Methods
This study was designed as a one-month randomised, controlled pilot trial of CPAP (Trial
registration: ISRCTN55685305), with a 12-month cohort study follow-up, incorporating repeated
measures. Enrolment and testing of participants took place out with medical institutions in all four
nations of the United Kingdom.
Apart from a clinical diagnosis of Down syndrome, inclusion criteria were age ≥16 years
(considered to be legal adulthood in Scotland) [14], and ≥18 years of age in England, Northern Ireland,
and Wales.
The Scotland A Research Ethics Committee approved the study, registered as ISRCTN55685305.
Recruitment was undertaken in the context of a larger study conducted by us on the objective
and subjective prevalence of OSAHS in adults with DS [15]. Briefly, questionnaires and pre-paid
reply envelopes were sent to 5266 UK-based adults with Down syndrome and their caregivers
between 14.02.2011 and 10.01.2014. Potential study participants were identified by local and national
organisations supporting people with Down syndrome (see Acknowledgements). The questionnaire
comprised a section for completion by the individual with Down syndrome and a section for completion
by a relative/caregiver. Anthropometric, comorbidity, medication, demographic, and sleep disturbance
data (including frequency per week of snoring, witnessed apnoeas, nocturnal choking episodes,
frequent awakenings, unrefreshing sleep and daytime sleepiness) were collected. The pictorial version
of the Epworth Sleepiness Scale (pESS), [16] designed to enhance understanding and accessibility in a
broader adult population was also administered.
Based on the presence of symptoms commensurate with possible OSAS, participants were then
invited to undertake a home sleep study which was conducted using the Embletta® Gold™ (Embla
Systems LLC, Amsterdam, the Netherlands) cardio-respiratory polygraphy device. This is a Type3
device [17,18], with capacity to record multiple channels of physiological data. Home sleep apnoea
testing using Type3 polygraphy is recommended in national guidelines [18] and is routinely used in
clinical practice across the UK. Channels used in broad accordance with the AASM guidelines for
portable monitoring [18] were nasal airflow and snoring recorded via nasal pressure cannula, respiratory
effort recorded via thoracic and abdominal respiratory inductance plethysmography bands, SpO2
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recorded via pulse oximetry and body position recorded via an inbuilt position sensor. All studies were
manually validated and scored by one of two experienced Registered Polysomnographic Technologists
using standard software (Embla® RemLogic™ Embla Systems LLC, Amsterdam, The Netherlands)
in broad accordance with current international guidelines [17]. To ensure consistency of scoring,
inter- and intra-rater reliability scoring was conducted in randomly selected subsets of 10% of valid
studies with 90% concordance. Table 1 lists the type of respiratory events noted on scoring.
Table 1. Characteristics of randomisation groups at baseline—pre-CPAP (mean ± SD or median (IQR)
as appropriate). CPAP: continuous positive airway pressure.
Anthropometric,
Behavioural, and Sleep
Characteristics
Total
Included
Lifestyle CPAP p
n = 14 n = 14
Gender (males: females) 28 12:2 7:7 0.10
Age (years) 28 27 ± 8 29 ± 10 0.54
Body Mass Index (kg/m2) 27 30.0 ± 7.4 33.2 ± 8.3 0.29
Collar size (cm) 28 41.4 ± 4.2 41.6 ± 5.7 0.93
Karyotype
Trisomy 21
28
10 71.4% 10 71.4%
0.48
Translocation 0 0.0% 0 0.0%
Mosaic 2 14.3% 0 0.0%
Unknown/not tested 2 14.3% 4 28.6%
Level of intellectual disability:
Mild
28
0 0.0% 0 0.0%
0.70
Moderate 10 71.4% 8 57.1%
Severe 4 28.6% 6 42.9%
Profound 0 0.0% 0 0.0%
Living arrangements:
At home with parents
28
12 85.7% 13 92.9%
1.00Supported accommodation 2 14.3% 1 7.1%
Malocclusion:
A
28
2 14.3% 3 21.4%
0.88
B 4 28.6% 4 28.6%
C 0 0.0% 0 0.0%
D 8 57.1% 7 50.0%
Macroglossia 28 4 28.6% 5 35.7% 1.00
Gothic palate 28 13 92.9% 13 92.9% 1.00
Adenoidal facies 28 3 21.4% 3 21.4% 1.00
Mallampati Score:
Class I
28
1 7.1% 0 0.0%
0.18
Class II 1 7.1% 5 35.7%
Class III 7 50.0% 7 50.0%
Class IV 5 35.7% 2 14.3%
Pictorial Epworth Sleepiness Scale (pESS):
Self-rated 27 10 ± 5 11 ± 7 0.70
Carer-rated 20 10 ± 4 12 ± 6 0.36
Developmental Behaviour Checklist for Adults (DBC-A):
Disruptive behaviour
subscale (scale range 0–34) 28 5 (3–8) 4 (2–9) 0.84
Anxiety/Antisocial subscale
(scale range −2–14) 28 1 (−1–1) 0 (0–1) 0.87
Depressive subscale (scale
range 0–18) 28 2 (1–4) 1 (0–4) 0.73
Kaufmann Brief Intelligence Test (KBIT-2):
Raw score verbal 28 30.6 ± 17.6 31.9 ± 13.3 0.83
Raw score non-verbal 28 12.3 ± 6.3 14.4 ± 4.2 0.30
Scales of Independent Behaviour—Revised (SIB-R) Adaptive Behaviour Short Form:
Raw score 27 84.2 ± 14.6 80.1 ± 11.1 0.50
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Table 1. Cont.
Anthropometric,
Behavioural, and Sleep
Characteristics
Total
Included
Lifestyle CPAP p
n = 14 n = 14
CANTAB Paired Associates Learning (PAL):
Mean errors to success 27 4.5 ± 3.5 5.1 ± 2.9 0.62
First trial memory score 28 11.4 ± 7.4 9.9 ± 4.3 0.52
CANTAL Simple Reaction Time (SRT):
Mean correct latency (ms) 28 606.8 ± 346.2 557.3 ± 311.8 0.69
EQ-5D:
Mobility 28 0.0 (0.0–1.3) 0.0 (0.0–2.0) 0.60
Self-care 28 0.0 (0.0–1.3) 0.0 (0.0–1.3) 0.95
Usual activities 28 0.0 (0.0–2.0) 0.0 (0.0–1.3) 0.80
Pain/discomfort 28 1.0 (0.0–1.0) 0.0 (0.0–2.0) 0.84
Anxiety/depression 28 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.70
Health state (visual
analogue scale; %) 27 80 (65–90) 93 (75–100) 0.08
RAND SF-36:
Total percent 28 80.8 (63.2–85.0) 63.1 (40.1–81.7) 0.13
Physical functioning 27 90.0 (45.0–96.3) 65.0 (30.0–97.5) 0.26
Role limitations due to
physical health 28 100.00 (100.0–100.0) 100.0 (18.8–100.0) 0.19
Role limitations due to
emotional problems 28 100.0 (100.0–100.0) 100 (83.3–100.0) 0.73
Energy/fatigue 28 62.5 (48.8–65.0) 47.5 (32.5–55.0) 0.13
Emotional well-being 5 84.1 (76.2–84.1) 60.0 (32.0–60.0) 0.20
Social functioning 27 100.0 (71.9–100.0) 87.5 (68.8–100.0) 0.38
Pain 28 50.0 (49.4–90.0) 50.0 (40.6–80.0) 0.27
General health 28 80.0 (62.5–95.0) 75.0 (47.5–95.0) 0.76
General Health Questionnaire 12-item version (GHQ12):
Total score 27 10.7 ± 2.5 10.5 ± 3.9 0.84
Modified carer burden inventory (CBI):
Total score 27 10.8 ± 7.0 9.0 ± 6.7 0.51
Objective sleep study variables on home-based polygraphy:
Total recording time (min) 25 525.5 ± 102.6 475.2 ± 104.9 0.24
Apnoeas/Hypopnoeas per
hour in bed 24 25.0 (15.8–46.5) 31.1 (14.1–50.1) 0.78
Supine 24 27.3 (17.2–46.4) 50.1 (16.9–97.3) 0.28
Non-supine 24 17.7 (6.0–24.3) 20.1 (7.4–36.8) 0.39
Obstructive 24 4.0 (1.1–9.9) 3.4 (1.2–23.7) 0.73
Central 24 0.2 (0.0–0.7) 3.9 (0.0–2.2) 0.277
Mixed 24 0.0 (0.0–0.2) 0.0 (0.0–0.0) 0.42
Hypopnoea 24 21.9 (11.9–30.5) 22.7 (12.2–33.0) 1.00
Mean SpO2 (%) 24 93.3 ± 4.2 94.4 ± 2.3 0.42
SpO2 nadir (%) 24 81.3 ± 8.9 80.7 ± 9.2 0.88
Average desaturation (%) 24 5.0 ± 0.8 6.0 ± 1.4 0.04
Oxygen desaturation index
per hour in bed 23 7.5 (2.1–23.7) 7.3 (1.6–21.9) 1.00
Participants with ≥10 apneas/hypopneas per hour in bed on Type 3 home polygraphy (Embletta®
Gold™; Embla Systems LLC, Amsterdam, the Netherlands) and symptoms consistent with OSAS were
invited to participate in the CPAP-trial. Ability to give informed consent and comply with the protocol
(participant or welfare guardian/attorney consent, as appropriate) was necessary. Exclusion criteria
were previous exposure to CPAP therapy, arterial oxygen saturation <90% on room air, a history of
chronic heart failure or recent myocardial infarction, known moderate or severe dementia, severe
behavioural problems that would preclude sleep studies or CPAP treatment, inability to comply with
the protocol.
Figure 1 summarizes the steps in the study. After discussing the results of the home sleep study
and with baseline assessments undertaken, participants were randomized by a blinded investigator
using balanced block design to CPAP treatment with conservative lifestyle advice or conservative
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lifestyle advice alone. The latter comprised written advice on diet, exercise, sleep hygiene and sleeping
position only. In the CPAP and lifestyle arm, CPAP therapy was initiated and monitored by an
unblinded, experienced research nurse. Auto-titrating CPAP devices were used (S8 AutoSet Spirit
II™; ResMed (UK) Ltd., Abingdon, UK). All participants received a patient folder containing diaries
to complete monthly for the duration of the study and to document any side-effects or difficulties
with treatment. Control participants (lifestyle only) were offered CPAP-treatment after 1 month, with
additional follow-up at 1-month post-initiation (visit 4 was incorporated to ensure the same follow-up
input as for the group initiated on CPAP at randomization). All study participants were reassessed at 3,
6, and 12 months. The CPAP machines were downloaded to a personal computer and information on
usage, mask to face time and residual apnoeic events were recorded using the inbuilt logging systems.
At the end of the 12-month follow-up visit, all participants using CPAP were integrated into a standard
clinical care pathway at their geographically closest sleep service.
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2.1. Study-Specific Measures
Height, weight, neck circumference and craniofacial features (presence of macroglossia, gothic
palate, adenoidal facies, malocclusion, and tonsillar enlargement) were assessed using standardised
techniques [1]. Data obtained on the sleep studies were also recorded.
2.2. Cognitive Function Tests
Participants completed cognitive function tests at baseline, one month, three months, and six
months. Sleepiness, behaviour, cognitive function and general health were measured at the same time
on each visit at the participant’s home to minimize circadian effects on performance [19]. The primary
outcome, subjective sleepiness, was assessed using the pictorial Epworth Sleepiness Scale (pESS) [16].
Cognitive and adaptive function were assessed using the Arizona Cognitive Test Battery (ACTB) [20]:
CANTAB Paired Associates Learning (PAL) and Simple Reaction Time (SRT) (Cambridge Cognition Ltd.,
Cambridge, UK); Modified Dots Task (Frogs and Cats; Down Syndrome Research Group, University
of Arizona); Kaufmann Brief Intelligence Test (KBIT-2; Pearson Clinical Assessment, San Antonio,
TX, USA); and carer-rated Scales of Independent Behaviour Revised (SIB-R; Riverside Publishing
Company, Rolling Meadows, IL, USA). Unfortunately, some data for the Modified Dots task was
overwritten due to operator error, and no baseline data were available; data were recovered for the
majority of patients for visits 4 and 7 only. All tests were administered by a single researcher who
remained blinded to allocation status, CPAP-use and any personal information at all times.
General health was assessed using the EQ-5D [21] and RAND SF-36 [22]. The printed RAND
SF-36 issued to participants in the early stages of the study omitted question 28 in error, resulting
in missing data for the majority of participants and rendering outcomes for this domain invalid.
Relatives/carers were also asked to complete questionnaires at baseline, 1 month, 3 months, 6 months
and 12 months in addition to open-ended qualitative questions about their experiences of caring [23].
Behavioural and emotional disturbance were assessed using the Developmental Behaviour Checklist
for Adults subscales (DBC-A) for disruptive behaviour, anxiety/antisocial behaviour and depressive
behaviour [24]. Additional questionnaires included the General Health Questionnaire (GHQ-12) [25],
the pESS [16] with relatives/carers independently rating the participant’s sleepiness.
2.3. Monthly Diary
Participants and relatives/carers were asked to fill out a diary during the 12-month period.
This was used to record GP and hospital visits, caffeine intake, medication and CPAP side-effects.
All questionnaires were filled in at each visit by participants assisted by a relative/carer as appropriate
to allow for objective evaluation. The same individual was required to fill in the questionnaires
throughout the study to maintain internal consistency.
2.4. Statistical Analysis
Based on a questionnaire study we conducted in over 5000 adults with DS [15], we expected over
100 people to respond to an invitation to participate in the CPAP trial. Due to unreasonable delays by
the local ethics committee and funding constraints, this recruitment rate was not achieved in the time
period of the study (2011–2015).
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A primary analysis by ‘intention to treat’ was initially planned with a second ‘per-protocol’
analysis excluding participants who had abandoned CPAP therapy during the pilot, randomised
controlled trial. The intention to treat analysis was deployed for the first part of the study (randomised,
parallel controlled trial at 1 month) only. Based on a previous study conducted in our department,
in patients from the OSAHS general population [26], the proposed sample size was calculated to
provide 90% power to show large differences of 0.8 SD between treatment groups (using general health
indices and the pESS) in the randomised, pilot trial. In order to achieve a power of 80% we aimed to
recruit a minimum of 26 participants into each arm of the study. Since there was no published data at
the time on adherence rates to CPAP therapy in adults with DS, we made allowance for a drop-out rate
of 10% based on previous studies. Since the adult DS population is finite, we were willing to accept
that any dropouts would lead to a small decrement in study power.
Statistical analyses were conducted using SPSS Statistics version 19 (IBM Corp, Armonk, NY, USA).
All analyses were two-tailed, with significance set at p = 0.001 due to multiple testing. All variables
were normality-checked. Discrete variables were evaluated using the Chi-square test and continuous
variables using Student’s t-test. Pearson’s and Spearman’s rank correlations were used to explore
correlations between parametric and non-parametric variables respectively. The Mann-Whitney
U test was used for non-parametric variables. Binary logistic regression (categorical variables),
generalized linear modelling (continuous variables) and multivariate regression were undertaken
to explore associations between the variable/s of interest and relevant independent and dependent
factors. These analyses were used to explore predictors of CPAP-use and the effects of total hours of
CPAP-use over 12 months on changes in behaviour, KBIT-scores and the pESS. Results are presented
as mean ± standard deviation for parametric variables, median with interquartile range (IQR 25–75%)
for non-parametric data, or as number and percentage. One-month assessments were analysed as
a randomized, controlled trial of CPAP therapy versus conservative lifestyle measures. Thereafter,
individuals in the lifestyle group commenced CPAP and all study participants were pooled into a
single group and analysed as a prospective cohort study. Data were entered blind to randomization
for the pilot study. At the end of 12 months, all data were locked, and analysis was undertaken by a
researcher blinded to CPAP adherence and any additional personal information.
3. Results
Figure 2 summarises participation data. Of 97 eligible participants, 28 (19 males; nine females)
were enrolled and randomised. Twenty-four participants completed the full 12-month study. Of this
group, one individual withdrew prior to 12 months due to family bereavement but completed and
returned participant and caregiver questionnaires by post at 12 months. In the event of participant
withdrawal, the CPAP machine was retrieved and downloaded, allowing compliance data to be
obtained up to the time of withdrawal from the study.
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3.1. Participant Characteristics
No significant differences in anthropometric data by sex were saw Table 1. Most participants
(71%) reported a Trisomy 21 karyotype and 7% reported mosaicism; 21% did not know their karyotype.
Participants had moderate (64%) to severe (36%) intellectual disability. Eighty-nine percent lived
at home with parent(s), the remaining 11% lived in supported accommodation. The mean age of
participants was 28 ± 9 years. Twenty-six percent had a normal BMI; the remainder were overweight
or obese. Mean BMI was 31.5 ± 7.9 kg/m2, with a higher mean BMI in females (37.4 ± 6.9 kg/m2;
p = 0.009). BMI and collar size did not change over the 12-month period.
3.2. Randomized, Controlled Pilot Trial of CPAP Therapy versus Conservative Lifestyle Measures
At one-month post-randomisation, no significant between-group differences were observed
(data not shown). Actual CPAP use by the treatment group at 1-month averaged 36 ± 9 days
from CPAP initiation with 35.7% (0.0–52.6%) of used days averaging ≥4 h usage, the conventionally
accepted therapeutic minimum in the general population [27]. The mean 95th centile pressure was
8.9 ± 2.8 cmH2O, with a mean leak within normal limits (0.3 L/s (0.2–0.4) L/s). Pressure, leak, and AHI
data were unavailable for one participant due to machine error.
3.3. Prospective Treatment Trial
The lifestyle group did not change significantly between baseline and one-month visits (pre-CPAP).
Therefore, the lifestyle group baseline measures were pooled with the CPAP group baseline measures
for use in the whole group prospective, treatment study analysis. Sleepiness, behaviour, cognitive
function, and general health outcomes for the whole group on CPAP over 12 months are summarized
in Tables 2 and 3.
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Table 2. Comparison of whole group at baseline and 12 months (mean ± SD or median (IQR) as appropriate).
Baseline Visit 12 Month Visit
n = 28 n = 24
Participant Characteristics Total Included Value Total Included Value p
Body Mass Index (kg/m2) 26 31.0 ± 7.5 23 32.5 ± 7.3 0.16
Collar size (cm) 27 41.3 ± 4.9 24 41.7 ± 5.3 1.00
Developmental Behaviour Checklist for Adults (DBC-A):
Disruptive behaviour subscale (scale range 0–34) 28 4 (2–8) 23 1 (0–3) <0.0001
Anxiety/Antisocial subscale (scale range −2–14) 28 0 (−1–1) 23 0 (−1–0) 0.03
Depressive subscale (scale range 0–18) 28 1 (1–4) 23 0 (0–1) 0.001
Pictorial Epworth Sleepiness Scale (pESS):
Self-rated 27 11 ± 6 24 6 ± 5 0.001
Carer-rated 20 11 ± 5 16 7 ± 5 0.03
Kaufmann Brief Intelligence Test (KBIT-2):
Raw score verbal 28 31.3 ± 15.3 24 37.4 ± 18.6 0.001
Raw score non-verbal 28 13.4 ± 5.4 24 19.5 ± 17.1 0.01
Scales of Independent Behaviour—Revised (SIB-R) Adaptive Behavior Short Form:
Raw score 27 82.6 ± 12.9 22 85.4 ± 12.5 0.33
CANTAB Paired Associates Learning (PAL):
Mean errors to success 27 4.9 ± 3.2 22 4.5 ± 3.8 0.44
First trial memory score 28 10.6 ± 6.0 24 12.0 ± 6.6 0.24
CANTAL Simple Reaction Time (SRT):
Mean correct latency (ms) 28 582.1 ± 324.3 24 599.1 ± 289.9 0.43
Brain Sci. 2020, 10, 0844 11 of 21
Table 3. Change (∆) from baseline in whole group at 1, 3, 6, and 12 months on CPAP (mean ± SD or median (IQR) as appropriate).
1 Month Post-CPAP
Initiation 3 Month Visit 6 Month Visit 12 Month Visit
n = 27 n = 26 n = 26 * n = 25 *
Participant characteristics Totalincluded
∆ from
baseline p
Total
included
∆ from
baseline p
Total
included
∆ from
baseline p
Total
included
∆ from
baseline
Developmental Behaviour Checklist for Adults (DBC-A):
Disruptive behaviour
subscale (scale range 0–34) 26 −1.38 ± 2.61 0.01 26 −2.65 ± 3.65 0.001 24 −2.50 ± 3.43 0.002 23 −3.13 ± 3.11
Anxiety/Antisocial subscale
(scale range −2–14) 26 −0.58 ± 1.30 0.03 26 −0.54 ± 1.29 0.05 24 −0.42 ± 1.14 0.09 23 −0.48 ± 0.95
Depressive subscale
(scale range 0–18) 26 −0.96 ± 2.24 0.04 26 −1.65 ± 2.94 0.01 24 −1.58 ± 2.87 0.01 23 −1.65 ± 2.66
Pictorial Epworth Sleepiness Scale (pESS):
Self-rated 26 −1.27 ± 5.94 0.29 25 −4.36 ± 5.37 <0.0001 24 −4.75 ± 5.61 <0.0001 24 −4.75 ± 6.23
Carer-rated 21 −1.33 ± 5.58 0.29 19 −3.00 ± 4.97 0.02 17 −4.29 ± 6.57 0.02 16 −3.44 ± 5.70
Kaufmann Brief Intelligence Test (KBIT-2)
Raw score verbal 25 3.20 ± 5.45 0.01 26 4.04 ± 5.99 0.002 25 3.88 ± 6.55 0.01 24 4.42 ± 5.88
Raw score non-verbal 25 5.16 ± 15.21 0.10 26 4.92 ± 12.15 0.05 25 4.92 ± 12.08 0.05 24 6.13 ± 14.79
Continuous positive airway
pressure (CPAP):
Total
included Raw value p
Total
included
∆ from
1 month p
Total
included
∆ from
1 month p
Total
included
∆ from
1 month
Total days since
CPAP initiation - 34 ± 9 - 26 41.77 ± 20.76 - 26 127.81 ± 20.03 - 25 318.48 ± 17.11
Days used (%) - 55.0 ± 34.5 - 26 −1.27 ± 12.3 0.61 26 0.10 ± 15.72 0.98 25 −3.80 ± 15.34
Days used ≥ 4 h (%) - 35.7 (0.0–84.0) - 26 −0.56 ± 6.43 0.66 26 1.70 ± 11.4 0.45 25 0.76 ± 15.96
Total usage (h) - 64.6 (8.2–143.3) - 26 117.01 ± 147.14 - 26 358.3 ± 365.07 - 25 812.74 ± 808.27
Mean usage (h) - 1.7 (0.2–4.5) - 26 −0.19 ± 1.15 0.41 26 −0.07 ± 1.21 0.79 25 −0.34 ± 1.25
Median usage (h) - 2.8 (1.1–6.7) - 26 −0.04 ± 0.46 0.68 26 0.10 ± 0.76 0.51 25 0.04 ± 1.04
95th centile pressure (cmH2O) - 8.2 ± 3.0 - 26 0.12 ± 1.4 - 26 0.16 ± 0.14 - 25 0.58 ± 1.79
95th centile leak (L/s) - 0.3 (0.2–0.5) - 25 ** −0.04 ± 0.26 0.50 25 ** −0.12 ± 0.40 0.16 24 ** −0.20 ± 0.48
Apnoea/Hypopnoea index
(derived from CPAP machine) - 9.7 (1.2–11.8) - 25 ** −0.23 ± 1.8 0.54 25 ** −0.66 ± 2.46 0.19 24 ** −1.10 ± 2.73
* Includes CPAP data from machine download of patient at withdrawal. ** No data due to machine error.
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3.4. Subjective Sleepiness
Mean self-rated pESS scores improved significantly across the 12 months, from 11 ± 6/24 at
baseline to 7 ± 6/24 at 3 months (p < 0.0001), and 6 ± 5/24 at 12 months (p = 0.001). There was an overall
downward trend in proxy-rated pESS scores across the 12 months on CPAP, although this did not reach
significance. A reduction in pESS scores was significantly associated with greater hours of CPAP use
over 12 months (B = −0.003; p = 0.039; CI95% −0.005–0.0001)
3.5. Cognitive and Adaptive Function
KBIT-2 verbal scores showed significant improvement at 12 months (p = 0.001), with a trend
towards improvement appearing at three months (p = 0.002). Mean baseline verbal score was 31 ± 15,
rising to 37 ± 19 at 12 months. Non-verbal subscale scores increased at three and 12 months but did not
reach statistical significance (p = 0.05, p = 0.01 respectively). The mean baseline score in this subscale
was 13 ± 5, rising to 20 ± 17 at 12 months. Individual performance on the KBIT-2 verbal and non-verbal
scores are shown in Appendix A.
3.6. Behavioural and Emotional Disturbances
A significant decrease in DBC-A Disruptive subscale scores was observed at 12 months in
comparison to baseline, indicating improvement in Disruptive behaviour (1(0–3) v. 4 (2–8); p < 0.0001),
and in severity and breadth of behavioural/emotional disturbance (both p < 0.0001). Similar reductions
were also noted in the three Depressive behaviour scores (all p = 0.001). No significant change was
evident in Anxiety/Antisocial behaviour scores, though a floor effect was noted. The change in
Disruptive behaviour scores exhibited a steady reduction from baseline, reaching significance at three
months (p = 0.001) which was maintained at 12 months (p < 0.0001). Regression analysis revealed
that only depressive scores were reduced significantly with total hours of CPAP use over 12 months
(B = −0.001; p = 0.026; CI95% −0.003–0.0001). Improvement in the disruptive scores was related
to improvement in depression only (B = −1.8; p < 0.0001; CI95% 0.42–1.2) suggesting significant
collinearity in these scores.
Individual changes on all 3 DBC-A subscales are shown in Appendix B.
3.7. General Health Measures
The reported EQ-5D visual analogue scale was 81 ± 19% overall at baseline; this did not differ
significantly over the course of the study, despite CPAP-use. Reported problems with mobility, self-care,
carrying out usual activities, pain/discomfort and anxiety/depression were all low at baseline, and did
not vary over the 12 months.
General health increased from as score of 74 ± 23% at baseline to 84 ± 21% at 12 months but was
not considered statistically significant (p = 0.02 at 3 months, p = 0.05 at 12 months).
No significant changes were evident in physical or emotional role limitation, energy/fatigue,
emotional wellbeing, social functioning or pain as measured using the RAND SF-36. Notably,
energy/fatigue scores were low at baseline, with a mean score of 50 ± 21%. This rose to 59 ± 20% after
12 months on CPAP (p = 0.14). The low number of participants with RAND SF-36 emotional wellbeing
scores should be noted (n = 5 at baseline and 3 months, and n = 4 at 12 months).
However, physical functioning increased significantly from baseline (68 ± 31%) to three
months (73 ± 30%; p < 0.0001); further increases at 12 months (78 ± 27%) did not reach statistical
significance (p = 0.03).
3.8. CPAP Compliance over Time
At 1-month post-CPAP initiation (mean duration from initiation = 39 ± 4 days), CPAP adherence
(n = 27) was generally low, with a mean usage of 1.7 h/night (0.2–4.5) h/night and a median usage of
2.87 h/night (1.1–6.7) h/night. CPAP was used on 55 ± 35% of days; the mean proportion of nights on
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which CPAP was used for ≥4 h was 35.7% (0.0–84.0%). The mean total usage was 64.6 h (8.2–143.3 h).
Mean 95th centile pressure was 8.2 ± 3.0 cmH2O and 95th centile leak fell within normal limits at
0.3 L/min (0.2–0.5) L/min. The mean machine-derived AHI was 9.7 h (1.2–11.8)/h in bed).
No significant changes were noted with respect to adherence, pressure, leak or AHI at 3, 6,
or 12 months post-CPAP initiation. Mean adherence at 12 months for 25 participants (352 ± 17 days
from CPAP initiation) remained low: mean usage 1.5 h/night (0.3–4.6) h/night; median usage 2.3 h/night
(01.0–6.4) h/night; days used 53.7 ± 33.7%; duration ≥4 h 34.3% (4.1–83.3%). The mean 95th centile
pressure was 8.6 ± 2.2 cmH2O, and the 95th centile leak was 0.3 ± 0.2 L/min. The mean AHI was 6.7/h
in bed (2.9–8.7/h).
Regression analysis did not reveal any significant associations between age, sex, BMI, AHI, oxygen
desaturation index, behaviour, or sleepiness at baseline with CPAP compliance at 12 months (Appendix C).
3.9. Acceptability of CPAP
All participants were fitted with full face masks, eight of whom required a mask change during
the trial. At 1 month, one participant reported mask-related skin irritation and another participant
reported anxiety related to the CPAP equipment. One participant withdrew due to inability to tolerate
CPAP. At three months, a further participant had withdrawn from the study due to CPAP-intolerance.
By 12 months, 24 participants remained in the study, with two participants having withdrawn due to
family bereavement, and moving into residential care, respectively. At the end of the study, 6 (25%)
participants reported some adverse events related to CPAP-use: anxiety (8%); intolerance (8%); skin
irritation (4%); wakening due to CPAP (4%). However, nineteen individuals elected to continue CPAP
at study completion.
Humidification was commenced in response to reported symptoms (e.g., nasal congestion,
dryness) using the unblinded nurse’s clinical judgement. Two individuals (7%) used humidification
at one month, four (15%) at three months, seven (28%) at six months, and seven (29%) at 12 months.
No significant differences were evident in CPAP outcomes between those using humidification and
those without (data not shown).
4. Discussion
This is the first randomized, controlled pilot study of CPAP therapy in adults with Down
syndrome and to date, the longest prospective study of CPAP in adults with DS. The reason for
offering controls in the pilot study the intervention at one-month post-randomisation was based on
short studies undertaken in the general population that have shown improvements after 4 weeks of
CPAP-use [28–30]. However, when designing the study, we did not factor in quite as many issues with
CPAP and mask-use as we experienced; this was unknown to us at the time. Despite the small number
of participants, real and significant improvements in sleepiness, behaviour, and daytime cognitive
function were demonstrated at 12 months whilst using CPAP.
To date, no other studies have systematically evaluated effectiveness and acceptability of CPAP
in the community-dwelling, DS population. Trois et al. reported in passing on the treatment of
adult DS individuals with OSA presenting to a sleep centre [31]. Nine of the 14 adults referred for
CPAP treatment were followed up by the researchers, one sought treatment elsewhere, and four
participants were lost to follow-up. CPAP was acceptable to the majority, with over half using therapy
for 6–8 h/night; their families reported subjective improvements in sleepiness and daytime function.
Two individuals did not accept CPAP, one quit due to side-effects, and one used CPAP sub-maximally;
these were similar results to ours. However, no formal assessment of sleepiness, cognition or behaviour
was undertaken, and no standard method for CPAP initiation and support was described.
There is some evidence, albeit not firmly conclusive, that CPAP improves cognitive function in
the general population with OSAS [9–11], but little is known about its impact in the Down syndrome
population. A study of the effects of CPAP on neurobehavioral outcomes in 52 children with OSAS
included 10 individuals with developmental delays, 6 of whom had Down syndrome [32]. Significant
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improvements in ESS, behaviour, and quality of life were reported, but the very small sample size
(n = 6) limits generalization of findings.
The AH requirement for entry to the treatment phase of this study was AH ≥ 10/h in bed.
General population studies have assessed the efficacy of treating mild OSAS with CPAP, with two
placebo-controlled studies of symptomatic individuals with an AHI in the mild range (5.0–14.9 events
per hour) demonstrating improvements in sleepiness, mood and daytime function, even with low
CPAP compliance [28,33]. Adults with Down syndrome may be more sensitive to the cognitive effects
of untreated OSAS given the existing cognitive impairment seen in this group, and so may stand to
benefit even when diagnosed with mild OSAS [34].
Similar studies in other neurological disorders, as well as in the older general population have
also defined lower AHI thresholds to account for possible differences in the aetiology of the sleep
disordered breathing and to minimise Type I error [33,35,36].
5. Conclusions
Despite small participant numbers, we demonstrated that CPAP-use lead to improvements in
subjective sleepiness, behavioural and emotional outcomes and cognitive function in a group of
community-dwelling individuals with DS and OSAS exhibiting moderate/severe intellectual disability.
Cognitive impairment and behavioural problems seen in adults with DS may be compounded by
untreated OSAS. Given the potential benefits in terms of improved daytime function and quality of
life, a further, larger-scale, randomized, controlled trial of CPAP in this population is warranted.
Limitations and Future Research
There are a number of limitations to this study. The study is small in size, unfortunately cut
short due to unacceptable delays in ethical approval which appear to be common for research in
individuals with intellectual disability, resulting in insufficient funding for the necessary duration of the
study [37,38]. However, it remains one of the largest, systematic studies of CPAP in community-dwelling
adults with DS worldwide, albeit underpowered (sample size 24). Despite the sample size and our
conservative significance threshold, marked improvements in sleepiness and scores of depression
were demonstrated. These positive results, alongside trends towards improvement in other domains,
suggest that a larger, multicentre trial is of merit.
No significant differences in outcomes between the two groups were evident after the one- month
randomised phase of the study. One month was selected as this length of time has been sufficient to
show a significant change in the general population [28–30], although other studies in the general
population have used longer periods up to 12 months [33]. Having now demonstrated that statistically
significant change occurs across a wide range of behavioural and intellectual parameters, further studies
could safely be randomised to three months of best supportive care only for the control group. Problems
with mask fit and comfort were encountered during this study, with many commercially available
CPAP interfaces proving to be too large for participants, even in the smallest sizes. All participants
were fitted with full-face masks due to obligate mouth breathing, on account of relative macroglossia
and low tone. Masks designed for individuals with DS, taking into account the midface hypoplasia and
short philtrum which is common in this group, may be required, and recent advances in 3D printing
technology may allow personalised masks modelled on each individual’s face to become an option in
the very near future.
It is our usual clinical practice to introduce heated humidification only as required due to CPAP
side-effects such as nasal congestion or dryness, and so a similar approach was taken in this study.
With hindsight, given the issues of increased mucus secretion and frequent respiratory tract infections in
individuals with DS, it may have been appropriate to start all participants on CPAP with humidification
from the outset. There is conflicting evidence as to whether humidification improves CPAP compliance,
with some studies demonstrating significant improvement [39] and others not [40]. Although some
participants did report side-effects and were later issued with humidification, it is possible that
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this contributed to reduced compliance. A study of fixed versus auto-titrating CPAP in the general
population noted a significant order effect, with neither type of device improving compliance but
participants preferring whichever they used first [41]; it is possible that a similar effect could be ascribed
to the use of humidification.
Given the small sample size, it was not viable to undertake the planned health economic analysis.
Health economic benefits of CPAP-use have been demonstrated in older adults in the general population,
despite modest compliance [33], and should be studied in adults with DS.
Changes were noted in pESS, KBIT-2 scores and DBC-A scores despite a low median usage of
CPAP across the group, and it would be of interest to assess whether these measures would improve
in a dose-dependent manner. Although steps were taken to encourage CPAP usage, future studies
might be able to employ additional strategies to increase adherence. Our group of DS adults were
all community-dwelling, resident throughout the United Kingdom and at the time of this study,
telemonitoring was not being deployed routinely across all sleep centres. Cognitive behavioural
interventions, self-management, peer support, intensive education and follow-up have all been shown
to improve CPAP compliance in the general population [42,43]. Incentivization via token economy
has been shown to increase adherence to physical activity programmes in individuals with Down
syndrome [44], offering many avenues to explore in the future. All in all, this study demonstrated that
the majority of adults with DS can tolerate CPAP, with 80% of those entering the study continuing after
12 months; its use as a standard treatment for OSAS in this group should not be ruled out.
Author Contributions: Concept: E.A.H., S.-A.C. and R.L.R.; Method: S.-A.C., E.A.H. and R.L.R.; Formal analysis:
E.A.H., L.J.W., G.S. and R.L.R.; Investigation: E.A.H. and D.M.F.; Data curation: E.A.H., D.M.F., G.S. and L.J.W.;
Writing: E.A.H., L.J.W., G.S., S.-A.C. and R.L.R.; Supervision: R.L.R. and S.-A.C.; Project administration: E.A.H.
and D.M.F.; Funding Acquisition: R.L.R., S.-A.C. and E.A.H. All authors have read and agreed to the published
version of the manuscript.
Funding: Chief Scientist Office, Scotland, Reference number CZH/4/549; Fondation Jerome Lejeune (grant);
University of Edinburgh grant number R41361-195RSP; Baily Thomas Charitable Trust (grant); Reference number
TRUST/RNA/AC/TM/2634-5178. The sponsors had no role in the design, execution, interpretation, or writing of
the study.
Acknowledgments: The authors wish to thank the individuals and families who participated in the study.
We acknowledge the vital roles played by Down’s Syndrome Scotland, the Down’s Heart Group, and the Down’s
Syndrome Association in identifying participants, mailing questionnaires and supporting the study. John Taffe
(Centre for Developmental Psychiatry and Psychology, Monash University, Australia) provided invaluable
assistance with scoring and interpretation of the DBC-A. We acknowledge the work of colleagues and research
associates within the Sleep Research Unit who assisted with questionnaire preparation and data entry.
Conflicts of Interest: The authors declare no conflict of interest.
Brain Sci. 2020, 10, 0844 16 of 21
Appendix A. Individual Performance on the KBIT-2 Verbal and Non-Verbal Scores at Baseline
and at 12 Months
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Appendix B. Individual Scores on the Three Developmental Behaviour Checklist for Adults
(DBC-A) Subscales at Baseline and at 12 Months: Disruptive Behaviour Scale, Anxiety/Antisocial
Scale, Depressive Scale
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Appendix C. Determinants of CPAP Usage at 12 Months Assessed by Generalised
Linear Modelling
Table A1. Determinants of CPAP usage at 12 m assessed by generalised linear modelling.
Variable TotalIncluded
Determinants
Remaining in Model Estimate 95% CI Lower 95% CI Upper p
Total usage
(h) at 12 m * 24
ID level
(moderate; severe) −942.13 −1774.77 −109.49 0.03
Age −38.80 −82.44 4.75 0.08
Gender −161.32 −986.60 663.97 0.70
BMI −14.00 −62.10 34.10 0.57
pESS (self-rated) −83.47 −156.01 −10.93 0.02
Median
CPAP usage
(h) at 12 m *
24
ID level
(moderate; severe) −3.52 −6.39 −0.64 0.02
Age −0.13 −0.29 0.02 0.08
Gender −0.65 −3.50 2.20 0.66
BMI −0.11 −0.28 0.06 0.19
pESS (self-rated) −0.28 −0.53 −0.03 0.03
Median CPAP
usage ≥4 h
at 12 m **
ID level
(moderate; severe) 0.11 0.01 2.31 0.16
Age 0.87 0.71 1.069 0.19
Gender 0.42 0.02 10.56 0.60
BMI 0.88 0.70 1.10 0.26
pESS (self-rated) 0.73 0.54 0.99 0.04
Determinants of CPAP usage at 12 m assessed by generalised linear modelling * or binary logistic regression ** as
appropriate. Estimate reported as β or Exp(B).
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